BL
TGTX icon

Bleichroeder LP’s TG Therapeutics TGTX Stock Holding History

Bleichroeder LP’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-75,000
Closed -$3.9M – 84
2020
Q4 		$3.9M Buy
75,000
+5,000
+7% +$169K 0.76% 23
2020
Q3 		$1.87M Buy
+70,000
New +$1.61M 0.34% 39

Other funds holding TGTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Bleichroeder LP's TGTX Position: Q1 2021 in Review

Bleichroeder LP sold out of TG Therapeutics (TGTX) in Q1 2021, closing a stake of 75,000 shares — an estimated $3.9M sold.

Bleichroeder LP first reported a position in TGTX in Q3 2020 and held it in 2 quarters. The position peaked at $3.9M in Q4 2020. 239 funds tracked by Wall St. Rank hold TGTX as of Q1 2021.

  • Bleichroeder LP reported no remaining TG Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Bleichroeder LP sold 75,000 TG Therapeutics shares in Q1 2021, an estimated $3.9M.
  • Bleichroeder LP first reported a position in TG Therapeutics in Q3 2020 and held it in 2 quarters.
  • Bleichroeder LP's TG Therapeutics position peaked at $3.9M in Q4 2020.
  • 239 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2021.

Based on Bleichroeder LP's 13F filing for Q1 2021, filed 17 May 2021.